Current Treatment Options in Oncology
ISSN 1527-2729 · Springer Science+Business Media · United States · active 1982–2026
Metrics
“Cites per paper” is a two-year cited-by rate computed from OpenAlex. It is not a Clarivate Journal Impact Factor — we neither compute nor license that metric. Citation rates differ enormously between fields, so compare within a discipline.
Is this the right journal for your paper?
The AI Journal Finder ranks the best-matched journals for your paper’s topic — with tier, open access, citation rate and predatory flags. Free to start.
Indexing & access
Access status: hybrid. Where this comes from publisher-level signals rather than works-level data it is a heuristic — confirm on the journal’s own site, especially regarding any article processing charge.
Scope
Frequently asked
Is Current Treatment Options in Oncology a predatory journal?
Our screening does not flag Current Treatment Options in Oncology. That is not a guarantee of quality — it means the venue is not on Beall's archive (frozen since 2017) and does not match our name-pattern heuristic. It is listed in Scopus, Web of Science, PubMed, which is a positive signal.
Is Current Treatment Options in Oncology indexed in Scopus or Web of Science?
Per our venue index, Current Treatment Options in Oncology appears in: Scopus, Web of Science, PubMed. Index membership changes over time — confirm on the index's own site before relying on it.
What is the impact factor of Current Treatment Options in Oncology?
Papers in Current Treatment Options in Oncology are cited about 5.7 times each within two years of publication, and Scimago places it in Q1, with an h-index of 89. Those are the open equivalents: the Clarivate Journal Impact Factor is a proprietary metric we neither compute nor license, so we show the two-year citation rate and Scimago quartile instead — they answer the same question of how heavily the journal is cited. A citation rate is a property of a field as much as of a journal.
What Scimago quartile is Current Treatment Options in Oncology (Q1, Q2, Q3, or Q4)?
Scimago places Current Treatment Options in Oncology in Q1 for its subject category. Quartiles split the journals in a field into four equal groups by SJR, so Q1 is the most-cited quarter and Q4 the least; Current Treatment Options in Oncology is cited about 5.7 times per paper over two years, with an h-index of 89. A journal is ranked per subject category, so one spanning several fields can sit in different quartiles depending on the category.
What is the Web of Science (JCR) quartile of Current Treatment Options in Oncology?
The Web of Science quartile comes from Clarivate's Journal Citation Reports (JCR), a proprietary product we neither license nor compute — so we cannot state a JCR quartile for Current Treatment Options in Oncology. The open equivalent is its Scimago quartile, Q1, derived from Scopus citation data. Because JCR ranks against Web of Science and Scimago against Scopus, the two can differ, so check Clarivate's site directly if you need the JCR quartile specifically.
Is Current Treatment Options in Oncology open access?
Our index records its access status as "hybrid". Where this is derived from publisher-level signals rather than works-level data it is a heuristic, so confirm on the journal's own site — particularly if an article processing charge matters to you.